Company intelligence / Profile preview

ARCHI MEDES

Ownership: Private
Development stage: Other

Overview

ARCHIMEDlife offers ISO 13485-certified medical laboratory services specializing in rare disease diagnostics, biomarker discovery, and validation. The company provides routine clinical testing using innovative technologies for small molecules and proteins. It partners with BIOCRATES for advanced metabolomics assays used in cardiometabolic disease, neurology, oncology, and other fields. No drug development or therapeutic clinical trial results are reported; the focus is on diagnostics.

Therapeutic areas: Rare DiseasesMetabolic DisordersNeurologyOncologyCardiovascular
Modalities: Diagnostic assayBiomarker testSmall molecule profilingProtein profiling
Industry: Protein Biomarker Diagnostics

Partnerships

BIOCRATES Life Sciences AG (metabolomics kit/service partnership)

Beyond the preview

Go deeper on ARCHI MEDES.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARCHI MEDES.

Explore the full profile